Neurophet, a Korean AI-powered brain imaging solutions provider, said it has opened a Connect & Development (C&D) incubation office within the Cambridge Innovation Center (CIC) in Boston, Massachusetts, as part of its strategy to accelerate global expansion and regulatory readiness in the U.S.

The company was selected in February for CIC’s C&D incubation support program under the Korea Health Industry Development Institute’s (KHIDI) “2025 Pharmaceutical Industry Global Expansion Consulting Support Program.”

CIC, located in Boston’s Kendall Square, is a shared office space established in 1999 and is home to many biotech startups and innovation-driven enterprises.

Through the CIC office, Neurophet aims to strengthen its capabilities in obtaining  FDA approval for its AI-based brain imaging analysis software.

The AI-backed healthcare company’s core products include Neurophet AQUA, a brain neurodegeneration imaging analysis software; Neurophet AQUA AD, a platform designed to monitor dementia drug prescriptions, treatment efficacy, and potential side effects; and Neurophet SCALE PET, a solution for quantitative analysis of PET (positron emission tomography) brain images.

Neurophet also intends to deepen cooperation with Boston-area neuroscience medical institutions and key opinion leaders to accelerate product development and regulatory approvals, expand partnerships with global pharmaceutical companies developing treatments for neurodegenerative diseases, including Alzheimer’s, dementia, and multiple sclerosis, and offer imaging analysis services to pharmaceutical and biotech firms conducting clinical trials worldwide.

“Based on our accumulated references, we plan to strategically supply our software products to medical institutions focused on Alzheimer’s disease, while actively seeking new sales channels,” Neurophet CEO Been Jun-kil said.